|
English
|
正體中文
|
简体中文
|
2830311
|
|
???header.visitor??? :
32543002
???header.onlineuser??? :
908
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"owonikoko t k"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2022 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
|
Kang, Y.-K.;Reck, M.;Nghiem, P.;Feng, Y.;Plautz, G.;Kim, H.R.;Owonikoko, T.K.;Boku, N.;Chen, L.-T.;Lei, M.;Chang, H.;Lin, W.H.;Roy, A.;Bello, A.;Sheng, J. |
| 臺大學術典藏 |
2021-04-23T05:56:25Z |
Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer
|
Nazha B.;Chih-Hsin Yang;Owonikoko T.K.; Nazha B.; CHIH-HSIN YANG; Owonikoko T.K. |
| 臺大學術典藏 |
2021-04-23T05:56:25Z |
Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer
|
Nazha B.;Chih-Hsin Yang;Owonikoko T.K.; Nazha B.; CHIH-HSIN YANG; Owonikoko T.K. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
